AMBEY — Ambey Laboratories Income Statement
0.000.00%
- IN₹990.39m
- IN₹1.38bn
- IN₹1.31bn
Annual income statement for Ambey Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2025 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 817 | 846 | 1,048 | 1,313 |
Cost of Revenue | ||||
Gross Profit | 154 | 157 | 149 | 143 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 752 | 772 | 993 | 1,246 |
Operating Profit | 65.2 | 73.8 | 55.2 | 66.7 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 30.9 | 48.3 | 62.2 | 60.4 |
Provision for Income Taxes | ||||
Net Income After Taxes | 103 | 35.7 | 45.7 | 47.8 |
Net Income Before Extraordinary Items | ||||
Net Income | 103 | 35.7 | 45.7 | 47.8 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 103 | 35.7 | 45.7 | 47.8 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 4.14 | 1.43 | 1.83 | 2.06 |